Physician profile
Beverly Cotner
NPI 1982905691
$4,491.08
in general payments reported to CMS, 2019-2025
29 companies · $570 in 2025
The $570 reported for 2025 was more than what 89% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,256 · 2022: $1,141 · 2023: $939 · 2024: $586 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,009.62 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $507.03 | 2021-2025 | |
| Astellas Pharma US INC | $371.97 | 2021-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $313.60 | 2021-2024 | |
| Agile Therapeutics, INC. | $239.86 | 2021-2024 | Twirla |
| Millicent US INC | $239.18 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Exeltis, USA INC. | $211.41 | 2021-2025 | Tyblume, Slynd |
| Avion Pharmaceuticals | $175.81 | 2021-2023 | Balcoltra |
| Organon LLC | $173.01 | 2021-2025 | Nexplanon |
| Therapeuticsmd, INC. | $153.29 | 2021 | |
| Evofem Biosciences, INC. | $149.07 | 2021-2022 | |
| Sage Therapeutics, LLC | $122.54 | 2021-2025 | Zurzuvae |
| Exact Sciences Corporation | $103.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $98.20 | 2024 | Zepbound, Jardiance |
| Hologic Sales and Service, LLC | $87.15 | 2023-2025 | Thinprep 2000 Processor, Aptima, Acessa Provu System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80.22 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $77.73 | 2021-2022 | |
| Scynexis, INC. | $55.65 | 2022 | |
| Sumitomo Pharma America, INC. | $54.57 | 2024 | Myfembree |
| Myovant Sciences INC. | $53.68 | 2022 | |
| Novo Nordisk INC | $42.84 | 2023-2025 | Wegovy |
| Roche Diagnostics Corporation | $34.10 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $32.00 | 2022 | |
| Mylan Pharmaceuticals INC. | $26.92 | 2021 | |
| Pharmacosmos Therapeutics INC. | $20.25 | 2025 | Monoferric |
| Davol INC. | $15.94 | 2023 | Channel Drain |
| Mission Pharmacal Company | $14.81 | 2021 | |
| Medtronic, INC. | $14.63 | 2022 | |
| Convatec INC. | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Cotner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.